 Tobias De La Garza Eckle
Concepts (357)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Ischemia | 16 | 2021 | 285 | 2.750 |
Why?
| | Receptor, Adenosine A2B | 16 | 2020 | 65 | 2.510 |
Why?
| | Period Circadian Proteins | 12 | 2022 | 33 | 2.360 |
Why?
| | Myocardial Reperfusion Injury | 11 | 2020 | 137 | 1.840 |
Why?
| | Circadian Rhythm | 9 | 2022 | 514 | 1.320 |
Why?
| | Myocardium | 12 | 2020 | 939 | 1.300 |
Why?
| | Acute Lung Injury | 7 | 2022 | 303 | 1.270 |
Why?
| | Adenosine | 19 | 2020 | 255 | 1.250 |
Why?
| | Reperfusion Injury | 7 | 2021 | 300 | 1.090 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 10 | 2019 | 298 | 1.070 |
Why?
| | Ischemic Preconditioning | 7 | 2017 | 47 | 1.010 |
Why?
| | Circadian Clocks | 3 | 2021 | 59 | 0.890 |
Why?
| | Myocardial Infarction | 13 | 2021 | 1209 | 0.870 |
Why?
| | Phototherapy | 4 | 2020 | 48 | 0.750 |
Why?
| | Mice | 47 | 2022 | 18365 | 0.660 |
Why?
| | Signal Transduction | 19 | 2018 | 5233 | 0.630 |
Why?
| | Apyrase | 6 | 2008 | 26 | 0.590 |
Why?
| | 5'-Nucleotidase | 6 | 2008 | 49 | 0.570 |
Why?
| | Animals | 56 | 2022 | 38109 | 0.570 |
Why?
| | Mice, Inbred C57BL | 26 | 2020 | 5997 | 0.540 |
Why?
| | Gene Expression Regulation | 7 | 2021 | 2609 | 0.540 |
Why?
| | Ischemic Preconditioning, Myocardial | 6 | 2015 | 35 | 0.530 |
Why?
| | Mice, Knockout | 20 | 2018 | 3125 | 0.520 |
Why?
| | Ischemic Postconditioning | 2 | 2014 | 3 | 0.480 |
Why?
| | Antigens, CD | 6 | 2008 | 555 | 0.470 |
Why?
| | Semaphorins | 1 | 2016 | 37 | 0.470 |
Why?
| | Cell Adhesion Molecules | 1 | 2016 | 178 | 0.450 |
Why?
| | Hypoxia | 5 | 2019 | 1199 | 0.440 |
Why?
| | Lung | 8 | 2022 | 4109 | 0.430 |
Why?
| | Pulmonary Alveoli | 5 | 2021 | 383 | 0.420 |
Why?
| | Transcription, Genetic | 3 | 2020 | 1496 | 0.420 |
Why?
| | Midazolam | 3 | 2020 | 72 | 0.410 |
Why?
| | Disease Models, Animal | 14 | 2020 | 4569 | 0.400 |
Why?
| | Myocytes, Cardiac | 4 | 2020 | 556 | 0.380 |
Why?
| | Succinate Dehydrogenase | 2 | 2021 | 67 | 0.380 |
Why?
| | Ganciclovir | 4 | 2004 | 53 | 0.380 |
Why?
| | Ischemia | 4 | 2011 | 421 | 0.370 |
Why?
| | Xanthines | 6 | 2012 | 22 | 0.360 |
Why?
| | MicroRNAs | 3 | 2017 | 701 | 0.350 |
Why?
| | Kidney | 6 | 2008 | 1496 | 0.340 |
Why?
| | Cardiovascular Diseases | 4 | 2021 | 2171 | 0.310 |
Why?
| | Cardiotonic Agents | 3 | 2017 | 95 | 0.310 |
Why?
| | Critical Illness | 2 | 2015 | 892 | 0.310 |
Why?
| | Inflammation | 8 | 2021 | 2880 | 0.310 |
Why?
| | Aminopyridines | 5 | 2012 | 127 | 0.310 |
Why?
| | Cytomegalovirus | 4 | 2004 | 168 | 0.290 |
Why?
| | Endothelium, Vascular | 3 | 2019 | 965 | 0.290 |
Why?
| | Propanolamines | 1 | 2019 | 40 | 0.290 |
Why?
| | Heart Ventricles | 2 | 2015 | 760 | 0.290 |
Why?
| | Polycythemia | 2 | 2009 | 25 | 0.280 |
Why?
| | Anesthesia Recovery Period | 1 | 2018 | 29 | 0.280 |
Why?
| | Blood Coagulation | 2 | 2020 | 268 | 0.280 |
Why?
| | Chronobiology Disorders | 1 | 2018 | 16 | 0.280 |
Why?
| | Amphiregulin | 1 | 2018 | 27 | 0.270 |
Why?
| | Flavones | 1 | 2018 | 11 | 0.270 |
Why?
| | Epinephrine | 1 | 2019 | 155 | 0.270 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 434 | 0.270 |
Why?
| | Shock, Hemorrhagic | 1 | 2020 | 201 | 0.270 |
Why?
| | Humans | 52 | 2021 | 144957 | 0.260 |
Why?
| | Glycolysis | 2 | 2017 | 340 | 0.260 |
Why?
| | Sleep | 1 | 2015 | 901 | 0.260 |
Why?
| | Anesthesia, General | 1 | 2018 | 118 | 0.260 |
Why?
| | Sunlight | 2 | 2015 | 78 | 0.260 |
Why?
| | Up-Regulation | 3 | 2017 | 852 | 0.260 |
Why?
| | Adenosine A2 Receptor Agonists | 3 | 2012 | 24 | 0.260 |
Why?
| | Erythropoietin | 2 | 2008 | 100 | 0.250 |
Why?
| | Delirium | 1 | 2018 | 104 | 0.250 |
Why?
| | ErbB Receptors | 1 | 2020 | 629 | 0.250 |
Why?
| | Neutrophils | 5 | 2015 | 1134 | 0.250 |
Why?
| | Pneumonia | 2 | 2021 | 631 | 0.240 |
Why?
| | Capillary Permeability | 2 | 2007 | 134 | 0.240 |
Why?
| | Light | 2 | 2020 | 411 | 0.240 |
Why?
| | Thoracic Surgery | 1 | 2018 | 144 | 0.240 |
Why?
| | Respiration, Artificial | 3 | 2011 | 708 | 0.240 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 2 | 2013 | 179 | 0.230 |
Why?
| | Equilibrative-Nucleoside Transporter 2 | 2 | 2013 | 3 | 0.230 |
Why?
| | Procollagen-Proline Dioxygenase | 3 | 2011 | 27 | 0.230 |
Why?
| | Heart Arrest, Induced | 1 | 2015 | 34 | 0.220 |
Why?
| | Endothelial Cells | 4 | 2017 | 870 | 0.220 |
Why?
| | Heart | 2 | 2017 | 636 | 0.220 |
Why?
| | Bone Marrow Cells | 2 | 2015 | 320 | 0.220 |
Why?
| | Organ Specificity | 2 | 2015 | 313 | 0.210 |
Why?
| | Drug Resistance, Viral | 3 | 2004 | 123 | 0.210 |
Why?
| | Cognitive Dysfunction | 1 | 2020 | 464 | 0.200 |
Why?
| | Phenylhydrazines | 1 | 2013 | 4 | 0.200 |
Why?
| | Sugar Phosphates | 1 | 2013 | 3 | 0.200 |
Why?
| | Extracellular Fluid | 3 | 2008 | 37 | 0.200 |
Why?
| | Carboxylic Acids | 1 | 2013 | 34 | 0.200 |
Why?
| | Anesthetics, Inhalation | 1 | 2014 | 52 | 0.200 |
Why?
| | Mice, Transgenic | 4 | 2021 | 2185 | 0.190 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2014 | 61 | 0.190 |
Why?
| | Carbohydrates | 1 | 2013 | 66 | 0.190 |
Why?
| | Echinococcosis | 1 | 2012 | 5 | 0.190 |
Why?
| | Cardiac Tamponade | 1 | 2012 | 14 | 0.190 |
Why?
| | Cell Line | 5 | 2019 | 2882 | 0.190 |
Why?
| | Tachycardia | 1 | 2012 | 57 | 0.190 |
Why?
| | Hernia, Hiatal | 1 | 2012 | 41 | 0.180 |
Why?
| | Critical Care | 2 | 2018 | 697 | 0.180 |
Why?
| | Pericardium | 1 | 2012 | 62 | 0.180 |
Why?
| | Sequence Analysis, RNA | 1 | 2015 | 442 | 0.180 |
Why?
| | Chest Pain | 1 | 2012 | 100 | 0.180 |
Why?
| | Cardiac Surgical Procedures | 1 | 2018 | 609 | 0.180 |
Why?
| | Echocardiography, Transesophageal | 1 | 2012 | 133 | 0.180 |
Why?
| | Cytomegalovirus Infections | 3 | 2004 | 206 | 0.180 |
Why?
| | Reperfusion | 1 | 2011 | 54 | 0.170 |
Why?
| | Stress, Mechanical | 1 | 2014 | 494 | 0.170 |
Why?
| | Platelet Aggregation | 2 | 2020 | 105 | 0.170 |
Why?
| | Tuberculosis, Meningeal | 1 | 2011 | 7 | 0.170 |
Why?
| | Fever of Unknown Origin | 1 | 2011 | 13 | 0.170 |
Why?
| | Coronary Occlusion | 1 | 2011 | 20 | 0.170 |
Why?
| | Inflammation Mediators | 2 | 2013 | 509 | 0.170 |
Why?
| | Neurologic Examination | 1 | 2011 | 131 | 0.160 |
Why?
| | Anesthesia | 1 | 2014 | 258 | 0.160 |
Why?
| | Respiratory Mucosa | 1 | 2013 | 322 | 0.160 |
Why?
| | Male | 23 | 2020 | 72406 | 0.160 |
Why?
| | Fatty Acids | 1 | 2013 | 452 | 0.160 |
Why?
| | Blood Platelets | 2 | 2020 | 400 | 0.160 |
Why?
| | Suture Techniques | 1 | 2011 | 131 | 0.160 |
Why?
| | Cardiac Myosins | 1 | 2020 | 37 | 0.150 |
Why?
| | Emigrants and Immigrants | 1 | 2012 | 158 | 0.150 |
Why?
| | Toll-Like Receptors | 1 | 2011 | 194 | 0.150 |
Why?
| | Renal Artery | 2 | 2007 | 43 | 0.150 |
Why?
| | Receptor, Adenosine A1 | 1 | 2009 | 11 | 0.150 |
Why?
| | Hemostasis | 1 | 2020 | 102 | 0.150 |
Why?
| | Heart Diseases | 1 | 2012 | 350 | 0.150 |
Why?
| | Extracellular Space | 1 | 2009 | 120 | 0.150 |
Why?
| | Thrombin | 1 | 2020 | 166 | 0.150 |
Why?
| | Viral Proteins | 2 | 2002 | 355 | 0.150 |
Why?
| | Adenosine A2 Receptor Antagonists | 4 | 2010 | 14 | 0.140 |
Why?
| | Acute Kidney Injury | 2 | 2007 | 866 | 0.140 |
Why?
| | RNA, Small Interfering | 4 | 2018 | 635 | 0.140 |
Why?
| | Extravascular Lung Water | 1 | 2008 | 9 | 0.140 |
Why?
| | Sp1 Transcription Factor | 1 | 2008 | 25 | 0.140 |
Why?
| | Mediastinal Neoplasms | 1 | 2009 | 51 | 0.140 |
Why?
| | Protein Biosynthesis | 1 | 2011 | 458 | 0.140 |
Why?
| | Cytoprotection | 1 | 2008 | 55 | 0.140 |
Why?
| | Cell Hypoxia | 3 | 2019 | 247 | 0.140 |
Why?
| | Ventilators, Mechanical | 1 | 2008 | 70 | 0.140 |
Why?
| | Transcriptome | 1 | 2015 | 1046 | 0.140 |
Why?
| | Coronary Artery Disease | 2 | 2013 | 741 | 0.140 |
Why?
| | Erythropoiesis | 1 | 2008 | 57 | 0.140 |
Why?
| | Paraganglioma | 1 | 2009 | 65 | 0.140 |
Why?
| | Heart Rate | 2 | 2009 | 855 | 0.130 |
Why?
| | Nervous System Diseases | 1 | 2011 | 284 | 0.130 |
Why?
| | Sequence Deletion | 1 | 2008 | 193 | 0.130 |
Why?
| | Antiviral Agents | 3 | 2004 | 768 | 0.130 |
Why?
| | Metabolomics | 1 | 2013 | 727 | 0.130 |
Why?
| | Connexin 43 | 1 | 2006 | 36 | 0.120 |
Why?
| | Lipopolysaccharides | 1 | 2010 | 863 | 0.120 |
Why?
| | Aquaporin 4 | 1 | 2007 | 98 | 0.120 |
Why?
| | Neutrophil Activation | 1 | 2006 | 85 | 0.120 |
Why?
| | Adenine Nucleotides | 1 | 2006 | 21 | 0.120 |
Why?
| | Mutation | 3 | 2009 | 4099 | 0.120 |
Why?
| | Dipyrone | 1 | 2005 | 1 | 0.120 |
Why?
| | Thrombosis | 1 | 2020 | 393 | 0.120 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2002 | 676 | 0.120 |
Why?
| | Phosphotransferases (Alcohol Group Acceptor) | 2 | 2002 | 49 | 0.120 |
Why?
| | Cells, Cultured | 5 | 2014 | 4155 | 0.110 |
Why?
| | Lung Injury | 1 | 2008 | 237 | 0.110 |
Why?
| | Immunity, Innate | 2 | 2011 | 846 | 0.110 |
Why?
| | Peroxidase | 3 | 2012 | 168 | 0.110 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2014 | 23 | 0.110 |
Why?
| | Viral Plaque Assay | 1 | 2004 | 29 | 0.110 |
Why?
| | Female | 16 | 2020 | 78376 | 0.100 |
Why?
| | Shock | 1 | 2005 | 108 | 0.100 |
Why?
| | Anaphylaxis | 1 | 2005 | 102 | 0.100 |
Why?
| | Receptors, Purinergic P1 | 3 | 2008 | 30 | 0.100 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2008 | 497 | 0.100 |
Why?
| | Adenosine Triphosphate | 1 | 2006 | 498 | 0.100 |
Why?
| | Mice, Mutant Strains | 3 | 2010 | 299 | 0.100 |
Why?
| | Positive-Pressure Respiration | 1 | 2004 | 112 | 0.100 |
Why?
| | Membrane Transport Proteins | 2 | 2006 | 154 | 0.100 |
Why?
| | Hippocampus | 2 | 2020 | 967 | 0.100 |
Why?
| | Dogs | 1 | 2014 | 438 | 0.100 |
Why?
| | Microbial Sensitivity Tests | 1 | 2004 | 371 | 0.090 |
Why?
| | Lung Diseases | 1 | 2009 | 787 | 0.090 |
Why?
| | Nerve Tissue Proteins | 1 | 2016 | 592 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 338 | 0.090 |
Why?
| | Electrocardiography | 3 | 2012 | 663 | 0.090 |
Why?
| | Chromatography, Liquid | 2 | 2013 | 454 | 0.080 |
Why?
| | Liver | 2 | 2016 | 1888 | 0.080 |
Why?
| | Cell Movement | 1 | 2006 | 965 | 0.080 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2003 | 278 | 0.080 |
Why?
| | Foscarnet | 1 | 2000 | 20 | 0.080 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 2 | 2013 | 20 | 0.080 |
Why?
| | Glucuronosyltransferase | 1 | 2000 | 18 | 0.080 |
Why?
| | Nucleotides | 2 | 2011 | 128 | 0.080 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2000 | 118 | 0.070 |
Why?
| | RNA, Messenger | 4 | 2008 | 2832 | 0.070 |
Why?
| | Acute Disease | 2 | 2012 | 1031 | 0.070 |
Why?
| | Receptor, Adenosine A2A | 2 | 2009 | 23 | 0.070 |
Why?
| | Suprachiasmatic Nucleus | 1 | 2018 | 19 | 0.070 |
Why?
| | Microarray Analysis | 1 | 2018 | 117 | 0.070 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2018 | 80 | 0.070 |
Why?
| | Resuscitation | 1 | 2020 | 302 | 0.070 |
Why?
| | Immunoblotting | 2 | 2013 | 300 | 0.070 |
Why?
| | Diagnosis, Differential | 2 | 2012 | 1495 | 0.070 |
Why?
| | Myosins | 1 | 2018 | 136 | 0.070 |
Why?
| | Phosphofructokinases | 1 | 2017 | 7 | 0.070 |
Why?
| | Integrases | 1 | 2018 | 122 | 0.060 |
Why?
| | Memory Disorders | 1 | 2018 | 194 | 0.060 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2004 | 923 | 0.060 |
Why?
| | Mice, Inbred Strains | 2 | 2008 | 397 | 0.060 |
Why?
| | Promoter Regions, Genetic | 2 | 2014 | 1258 | 0.060 |
Why?
| | Renal Circulation | 2 | 2007 | 75 | 0.060 |
Why?
| | Gene Expression | 2 | 2013 | 1490 | 0.060 |
Why?
| | Edema | 2 | 2007 | 124 | 0.060 |
Why?
| | Immunohistochemistry | 2 | 2012 | 1718 | 0.060 |
Why?
| | Hemodynamics | 1 | 2020 | 1121 | 0.060 |
Why?
| | Phenotype | 3 | 2013 | 3164 | 0.050 |
Why?
| | Time Factors | 4 | 2008 | 7183 | 0.050 |
Why?
| | Adoptive Transfer | 1 | 2015 | 198 | 0.050 |
Why?
| | Endothelium | 1 | 2015 | 119 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2032 | 0.050 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2018 | 300 | 0.050 |
Why?
| | Gene Deletion | 1 | 2015 | 389 | 0.050 |
Why?
| | Polymorphism, Restriction Fragment Length | 2 | 2004 | 64 | 0.050 |
Why?
| | Carbohydrate Metabolism | 1 | 2013 | 61 | 0.050 |
Why?
| | Lactates | 1 | 2013 | 83 | 0.050 |
Why?
| | Cell Respiration | 1 | 2013 | 107 | 0.050 |
Why?
| | Motor Activity | 1 | 2018 | 722 | 0.050 |
Why?
| | Dipyridamole | 1 | 2013 | 28 | 0.050 |
Why?
| | Pulmonary Edema | 1 | 2013 | 106 | 0.050 |
Why?
| | Codon | 2 | 2004 | 94 | 0.050 |
Why?
| | Albania | 1 | 2012 | 1 | 0.050 |
Why?
| | Mediastinal Cyst | 1 | 2012 | 1 | 0.050 |
Why?
| | Genes, Reporter | 1 | 2014 | 276 | 0.050 |
Why?
| | Pulmonary Gas Exchange | 1 | 2013 | 119 | 0.050 |
Why?
| | Principal Component Analysis | 1 | 2013 | 198 | 0.050 |
Why?
| | Switzerland | 1 | 2012 | 46 | 0.050 |
Why?
| | Brain | 2 | 2018 | 2941 | 0.050 |
Why?
| | Mutant Chimeric Proteins | 1 | 2012 | 6 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 2 | 2018 | 3869 | 0.050 |
Why?
| | Cell Transplantation | 1 | 2012 | 39 | 0.050 |
Why?
| | Length of Stay | 1 | 2018 | 1337 | 0.050 |
Why?
| | Sex Factors | 1 | 2018 | 2114 | 0.050 |
Why?
| | Carbon | 1 | 2013 | 203 | 0.040 |
Why?
| | Nucleosides | 1 | 2011 | 25 | 0.040 |
Why?
| | DNA-Directed DNA Polymerase | 2 | 2002 | 48 | 0.040 |
Why?
| | Anesthesiology | 1 | 2014 | 175 | 0.040 |
Why?
| | High-Throughput Screening Assays | 1 | 2013 | 175 | 0.040 |
Why?
| | Thalamic Diseases | 1 | 2011 | 3 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2012 | 2738 | 0.040 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 758 | 0.040 |
Why?
| | Spinal Puncture | 1 | 2011 | 17 | 0.040 |
Why?
| | Blood Pressure | 2 | 2009 | 1769 | 0.040 |
Why?
| | Vasodilator Agents | 1 | 2013 | 331 | 0.040 |
Why?
| | Myocardial Reperfusion | 1 | 2011 | 59 | 0.040 |
Why?
| | Cerebral Infarction | 1 | 2011 | 47 | 0.040 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2012 | 159 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 983 | 0.040 |
Why?
| | Perioperative Period | 1 | 2011 | 71 | 0.040 |
Why?
| | Adult | 4 | 2019 | 40506 | 0.040 |
Why?
| | Age Factors | 1 | 2018 | 3335 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3415 | 0.040 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2012 | 285 | 0.040 |
Why?
| | Delayed Diagnosis | 1 | 2011 | 95 | 0.040 |
Why?
| | Binding Sites | 1 | 2014 | 1331 | 0.040 |
Why?
| | Adaptive Immunity | 1 | 2011 | 169 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2013 | 636 | 0.040 |
Why?
| | Factor Va | 1 | 2020 | 2 | 0.040 |
Why?
| | Prothrombin | 1 | 2020 | 25 | 0.040 |
Why?
| | Factor Xa | 1 | 2020 | 35 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 851 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 577 | 0.040 |
Why?
| | Cell Death | 1 | 2011 | 383 | 0.040 |
Why?
| | Acetamides | 1 | 2010 | 38 | 0.040 |
Why?
| | Intraoperative Complications | 1 | 2011 | 156 | 0.040 |
Why?
| | Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2009 | 21 | 0.040 |
Why?
| | Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2009 | 19 | 0.040 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 292 | 0.040 |
Why?
| | Purines | 1 | 2010 | 187 | 0.040 |
Why?
| | Bone Marrow Transplantation | 1 | 2010 | 294 | 0.040 |
Why?
| | Chimera | 1 | 2008 | 61 | 0.040 |
Why?
| | Amino Acids, Dicarboxylic | 1 | 2008 | 9 | 0.040 |
Why?
| | Whole Blood Coagulation Time | 1 | 2008 | 3 | 0.040 |
Why?
| | Capillaries | 1 | 2009 | 124 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2010 | 575 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2014 | 916 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2012 | 781 | 0.030 |
Why?
| | Crotalid Venoms | 1 | 2008 | 32 | 0.030 |
Why?
| | Purinergic P1 Receptor Antagonists | 1 | 2007 | 10 | 0.030 |
Why?
| | Hemodilution | 1 | 2007 | 11 | 0.030 |
Why?
| | Adaptation, Physiological | 1 | 2012 | 570 | 0.030 |
Why?
| | Blood Gas Analysis | 1 | 2008 | 83 | 0.030 |
Why?
| | Enzyme Induction | 1 | 2007 | 88 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2008 | 381 | 0.030 |
Why?
| | Cell Membrane Permeability | 1 | 2007 | 85 | 0.030 |
Why?
| | Pressure | 1 | 2008 | 225 | 0.030 |
Why?
| | Adenosine Diphosphate | 1 | 2007 | 84 | 0.030 |
Why?
| | Cohort Studies | 1 | 2018 | 5965 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2014 | 1126 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2012 | 1217 | 0.030 |
Why?
| | Carbon Monoxide | 1 | 2007 | 82 | 0.030 |
Why?
| | Microcirculation | 1 | 2007 | 138 | 0.030 |
Why?
| | Species Specificity | 1 | 2008 | 574 | 0.030 |
Why?
| | Adenosine Monophosphate | 1 | 2007 | 86 | 0.030 |
Why?
| | Permeability | 1 | 2007 | 168 | 0.030 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 1 | 2006 | 39 | 0.030 |
Why?
| | Blood Vessels | 1 | 2008 | 171 | 0.030 |
Why?
| | Mitochondria | 1 | 2013 | 984 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2007 | 157 | 0.030 |
Why?
| | Nucleoside Transport Proteins | 1 | 2006 | 8 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2007 | 194 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2013 | 1786 | 0.030 |
Why?
| | Epithelium | 1 | 2007 | 314 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 2006 | 166 | 0.030 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2012 | 543 | 0.030 |
Why?
| | DNA, Complementary | 1 | 2006 | 277 | 0.030 |
Why?
| | Comorbidity | 1 | 2011 | 1660 | 0.030 |
Why?
| | Potassium | 1 | 2006 | 152 | 0.030 |
Why?
| | Troponin I | 1 | 2006 | 72 | 0.030 |
Why?
| | Arteries | 1 | 2007 | 259 | 0.030 |
Why?
| | Diskectomy | 1 | 2005 | 24 | 0.030 |
Why?
| | Child | 3 | 2018 | 22657 | 0.030 |
Why?
| | Cytokines | 1 | 2013 | 2065 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 2005 | 200 | 0.030 |
Why?
| | Intervertebral Disc Displacement | 1 | 2005 | 41 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2006 | 246 | 0.030 |
Why?
| | Electrodes, Implanted | 1 | 2005 | 115 | 0.030 |
Why?
| | Hemorrhage | 1 | 2020 | 809 | 0.030 |
Why?
| | Creatinine | 1 | 2006 | 506 | 0.030 |
Why?
| | DNA Fingerprinting | 1 | 2004 | 32 | 0.030 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2004 | 35 | 0.030 |
Why?
| | Prosthesis Implantation | 1 | 2005 | 153 | 0.030 |
Why?
| | Base Sequence | 1 | 2007 | 2191 | 0.030 |
Why?
| | Infant | 1 | 2018 | 10039 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 1195 | 0.030 |
Why?
| | Sepsis | 1 | 2010 | 641 | 0.030 |
Why?
| | Stroke | 1 | 2013 | 1258 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2008 | 897 | 0.020 |
Why?
| | Adolescent | 2 | 2018 | 22453 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2931 | 0.020 |
Why?
| | Child, Preschool | 1 | 2018 | 11799 | 0.020 |
Why?
| | Ultrasonography | 1 | 2007 | 770 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2004 | 340 | 0.020 |
Why?
| | Phosphorylation | 1 | 2006 | 1733 | 0.020 |
Why?
| | DNA, Viral | 1 | 2004 | 358 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2010 | 3550 | 0.020 |
Why?
| | Point Mutation | 1 | 2003 | 243 | 0.020 |
Why?
| | Aged | 2 | 2012 | 25947 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2002 | 415 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2004 | 824 | 0.020 |
Why?
| | Drug Resistance, Microbial | 1 | 2000 | 70 | 0.020 |
Why?
| | Viral Load | 1 | 2002 | 526 | 0.020 |
Why?
| | Polychlorinated Dibenzodioxins | 1 | 2000 | 10 | 0.020 |
Why?
| | Quercetin | 1 | 2000 | 18 | 0.020 |
Why?
| | Young Adult | 1 | 2017 | 14126 | 0.020 |
Why?
| | Teratogens | 1 | 2000 | 20 | 0.020 |
Why?
| | Caco-2 Cells | 1 | 2000 | 79 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2018 | 17101 | 0.020 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2000 | 60 | 0.020 |
Why?
| | Middle Aged | 3 | 2005 | 35928 | 0.020 |
Why?
| | Antioxidants | 1 | 2000 | 549 | 0.010 |
Why?
| | Biomarkers | 1 | 2006 | 4275 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2000 | 5417 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2000 | 11695 | 0.010 |
Why?
|
|
De La Garza Eckle's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|